

**AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) An isolated human antibody, comprising:  
human immunoglobulin VH-chain CDR1, CDR2, and CDR3 of a polypeptide  
consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6,  
respectively; and  
human immunoglobulin VL-chain CDR1, CDR2, and CDR3 of a polypeptide  
consisting of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12,  
respectively.

2. (Currently Amended) An isolated human antibody, comprising:  
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3;  
and  
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.

3. (Currently Amended) An isolated human antibody, comprising:  
ligation of a polypeptide consisting of an amino-acid sequence represented by SEQ  
ID NO: 3; and  
~~ligation of~~ a polypeptide consisting of an amino-acid sequence represented by SEQ  
ID NO: 9.

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Currently Amended) An isolated gene encoding the a human antibody ~~according~~  
~~to any one of Claims 1-3 and 5.~~ comprising:  
human immunoglobulin VH-chain CDR1, CDR2, and CDR3 of a polypeptide  
consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6,  
respectively; and  
human immunoglobulin VL-chain CDR1, CDR2, and CDR3 of a peptide consisting  
of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12, respectively.

8. (Currently Amended) The gene according to Claim 7, including as an open reading frame the nucleic acid sequence of a ~~base sequence represented by~~ SEQ ID NO: 1 or 7.

9. (Previously Presented) A recombinant expression vector, comprising the gene according to Claim 7.

10. (Previously Presented) A transformant, comprising the gene according to Claim 7 introduced therein.

11. (Previously Presented) A method for producing a human antibody against human interleukin-18 by causing a host to express the gene according to Claim 7.

12. (Currently Amended) A detector for human interleukin-18, the detector using either (1) the antibody according to any one of Claims 1-3 or 37-39 ~~and 5, or (2) a modified antibody comprising the human antibody according to any one of Claims 1 to 5 and a modification agent binding thereto.~~

13. (Currently Amended) An immunological disease diagnostic kit for measuring an amount of human interleukin-18 contained in a test sample the human interleukin-18 antibody according to any one of claims 1-3 or 37-39; and a carrier on which the human interleukin 18 antibody is immobilized, ~~by using either (1) the antibody according to any one of Claims 1-3 and 5, or (2) a human interleukin-18 detecting reagent including a modified antibody comprising the human antibody according to any one of Claims 1-3 and 5 and a modification agent binding thereto.~~

14. (Currently Amended) A method for diagnosing immunological disease in accordance with an amount of human interleukin-18 contained in a test sample ~~and the amount of human interleukin-18 being measured by using the detecting reagent according to Claim 13.~~ a human antibody, comprising:

human immunoglobulin VH-chain CDR1, CDR2, and CDR3 of a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6, respectively; and

human immunoglobulin VL-chain CDR1, CDR2, and CDR3 of a peptide consisting of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12, respectively.

15. (Cancelled)

16. (Currently Amended) ~~The~~ A human interleukin-18 activity inhibitor ~~according to Claim 15, wherein the~~ comprising a human interleukin-18 antagonist as an active ingredient, the human interleukin-18 antagonist being the human antibody according to any one of claims 1-3 or 37-39, ~~1-4, is any one of following substances selected from:~~

- ~~(i) the human antibody according to any one of Claims 1-3 and 5;~~
- ~~(ii) a modified antibody comprising the human antibody according to any one of Claims 1-3 and 5 and a modification agent binding thereto; and~~
- ~~(iii) a low molecular compound obtained through molecular designing in accordance with an antigen determining region on human interleukin 18, the antigen determining region being recognized by either (1) the antibody according to (i), or (2) the modified antibody according to (ii).~~

17. (Previously Presented) A gene therapy agent, comprising the gene according to Claim 7.

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Previously Presented) A recombinant expression vector, comprising the gene according to Claim 8.

26. (Previously Presented) A transformant, comprising the gene according to Claim 8 introduced therein.

27. (Currently Amended) A method for producing a human antibody against human interleukin-18 by causing a host to express the gene according to Claim 8, the human antibody being produced by the expression of the gene.

28. (Previously Presented) A gene therapy agent, comprising the gene according to Claim 8.

29. (Currently Amended) ~~A immunological disease treatment agent, comprising the~~  
The human interleukin-18 activity inhibitor according to Claim 16, which is used for treating immunological disease.

30. (Canceled)

31. (New) An isolated gene encoding a human antibody, wherein the gene encodes:  
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3;  
and  
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.

32. (New) An isolated gene encoding a human antibody, wherein the gene encodes:  
ligation of a polypeptide consisting of an amino-acid sequence represented by SEQ  
ID NO: 3 a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO:  
9.